SCHEMBL19627638

SCHEMBL19627638

COc1ccc(CN(c2nccs2)S(=O)(=O)c2ccc(NC3CN(C(=O)OC(C)(C)C)C[C@@H]3C)c(Cl)c2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 5/20 0.40
SCN1A P35498 4/20 0.40
ADAM17 P78536 3/20 0.35
MMP1 P03956 2/20 0.34
MMP9 P14780 2/20 0.34
MMP3 P08254 1/20 0.34
MMP7 P09237 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
AXL P30530 1/20 0.34
MERTK Q12866 1/20 0.34
PIK3CA P42336 2/20 0.33
PRKDC P78527 2/20 0.33
MTOR P42345 1/20 0.33
BMP1 P13497 1/20 0.33
GPR119 Q8TDV5 2/20 0.33
MMP13 P45452 1/20 0.33
TP53 P04637 2/20 0.33
STS P08842 1/20 0.33
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19627639 1.00 SCN8A (0.40) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19614104 0.94 SCN8A (0.40) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19613802 0.94 SCN8A (0.40) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19613799 0.94 SCN8A (0.40) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19613798 0.94 SCN8A (0.40) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19631573 0.94 SCN8A (0.40) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19631666 0.94 SCN8A (0.40) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19614100 0.94 SCN8A (0.40) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19627625 0.93 SCN8A (0.37) SCN8ASCN1AADAM17MMP1MMP9
SCHEMBL19627633 0.89 CNR1 (0.41) SCN8ASCN1AMMP1MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885ADAM17 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.